Keywords: Astellas, Ambit Biosciences, FLT3 kinase inhibitors, Licensing
Ambit sells rights for FLT3 Kinase inhibitors to Japan’s Astellas for up to $390 million
Article | 18 December 2009
Leading Japanese drugmaker Astellas Pharma has entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
